Continuous lenalidomide improves overall survival in multiple myeloma

被引：0
|
作者：
不详
机构：
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2011年 / 72卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：309 / 309
页数：1
相关论文
共 50 条
  • [31] Lenalidomide maintenance for multiple myeloma
    Brower, Vicki
    LANCET ONCOLOGY, 2012, 13 (06): : E238 - E238
  • [32] Lenalidomide in the treatment of multiple myeloma
    Rao, Kamakshi V.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (17) : 1799 - 1807
  • [33] UPDATED OVERALL SURVIVAL ANALYSIS OF THE FIRST STUDY: CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE VS MELPHALAN, PREDNISONE, AND THALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Facon, T.
    Dimopoulos, M. A.
    Hulin, C.
    Benboubker, L.
    Belch, A.
    Ludwig, H.
    Pinto, A.
    Attal, M.
    Cavo, M.
    Moreau, P.
    Schots, R.
    Meuleman, N.
    Weisel, K.
    Tiab, M.
    Lee, J. J.
    Butler, A.
    Marek, J.
    Chen, G.
    Ervin-Haynes, A.
    Fermand, J. P.
    HAEMATOLOGICA, 2015, 100 : 3 - 3
  • [34] Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma
    Brinker, BT
    Waller, EK
    Leong, T
    Heffner, LT
    Redei, I
    Langston, AA
    Lonial, S
    CANCER, 2006, 106 (10) : 2171 - 2180
  • [35] Overall survival as a primary end point in multiple myeloma trials
    Cliff, Edward R. Scheffer
    Rehman Mohyuddin, Ghulam
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (09) : 565 - 566
  • [36] Trends in overall survival and costs of multiple myeloma, 2000–2014
    R Fonseca
    S Abouzaid
    M Bonafede
    Q Cai
    K Parikh
    L Cosler
    P Richardson
    Leukemia, 2017, 31 : 1915 - 1921
  • [37] Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
    Sarah A. Holstein
    Vera J. Suman
    Philip L. McCarthy
    Current Hematologic Malignancy Reports, 2019, 14 : 31 - 38
  • [38] Body mass index and overall survival in multiple myeloma.
    Wang, Bei
    Derman, Benjamin Avi
    Langerman, Spencer
    Stepniak, Elizabeth
    Johnson, Julie
    Zhang, Wei
    Jakubowiak, Andrzej J.
    Chiu, Brian C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
    Holstein, Sarah A.
    Suman, Vera J.
    McCarthy, Philip L.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 31 - 38
  • [40] Impact of Frailty on Overall Survival of Elderly Patients With Multiple Myeloma
    Schutz, Natalia
    Smietniansky, Maximiliano
    Otero, Victoria
    Fantl, Dorotea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E50 - E50
12345